Novel Risk Factors and Localization of Peripheral Arterial Disease (GWADAOMI)

Centre Hospitalier Universitaire de la Guadeloupe

Status: Completed

Conditions: Guadeloupe; Hemoglobin A1c Protein, Human; Atherosclerotic Peripheral Arterial Disease

Study type: Observational

Funder types: Other

Identifiers

NCT07233356

PAP_RI2_2017/10

Details and patient eligibility

About

Background: .Atherosclerotic peripheral arterial disease (PAD) is associated with a high risk of mortality, coronary events and stroke. The distal localization is frequently associated with amputation. Patients from African origin have a higher prevalence of PAD independently of age and other risk factors. In Guadeloupe, French West Indies, infra popliteal localization is more frequent than in France continental associated with different risk factors (88% of hypertension, 2/3 of diabetes).

Purpose: Traditional risk factors of PAD are smoking diabetes, hypertension, high lipid levels, age, and family history of cardiovascular events. The role of novel risk factors in PAD has recently been shown: fibrinogen, CRP-us, homocysteine, interleukin 6, the neutrophil-to-lymphocyte ratio, the urinary albumin-to-creatinine ratio, alkaline phosphatases, insulin resistance, uric acid, D dimer, vitamin D deficiency, HBA1C. Thus the purpose of the research is to study the role of novel risk factors in the occurrence of infrapopliteal PAD. The primary criterion is the HBA1C.

Full description

In Guadeloupe, French West Indies, a high prevalence of distal (infra popliteal) PAD has been observed compared to France continental, the risk factors associated with the distal localization are diabetes and hypertension. Novel risk factors in PAD have been highlighted such as fibrinogen, CRP-us, homocysteine, interleukin 6, the neutrophil-to-lymphocyte ratio, the urinary albumin-to-creatinine ratio, alkaline phosphatases, insulin resistance, uric acid, D dimer, vitamin D deficiency. HBA1 C is also an independent novel risk factor of PAD in diabetic and non-diabetic patients. It seems that risk factors are different according to the localization of the disease. Thus the aim of the research is to study the role of novel risk factors in the localization of PAD. The primary outcome is the HBA1C. The secondary outcome is the role of other risk factors in the localization of PAD. This is a cross sectional study. Patients with PAD diagnosed with systolic pressure index< 0.9 or toe systolic pressure < 85 mmHg or tissue oxygen saturation <65 mmHg or with stenosis > 50 % or occlusion will be proposed to participate in the study. If the culprit lesion is infra popliteal they will be included in group 1. If the culprit lesion is supra or popliteal they will be included in group 2. Patients will be informed of the study and the written informed consent will be obtained. Clinical and para clinical date will be taken on the same date (V0). Then the patient will have to go to the Pointe à Pitre hospital within one month for a second visit (V1) where blood and urinary samples will be taken. Interleukin 6 and insulin in non-diabetic and blood collection will specially be taken for the study.

Enrollment: 123 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• men or women aged more than 18 years old
• with PAD diagnosed with systolic pressure index (SPI) <0.9 or toe systolic pressure <85 mmHg or tissue oxygen saturation < 65 mmHg or with stenosis >50 % or occlusion of one or more arteries
• Patients with or without diabetes
• with stenosis >50 % or occlusion of one or more arteries, infra popliteal, supra or popliteal
• wishing to take part in the study
• having signed the informed consent
• Patients affiliated or beneficiary of a social security scheme

Exclusion criteria

• Patients aged less than 18 years old
• Patients who do not wish to participate in the study
• Patients with PAD with localization infra popliteal and supra popliteal or popliteal (stenosis > 50 % or occlusion of an artery at supra popliteal or popliteal level AND infra popliteal level)
• Patients with an history of revascularization at supra popliteal, popliteal or infra popliteal level AND stenosis on a different territory.
• Patients with medial calcific sclerosis without PAD
• PAD from non-atherosclerotic origin
• Patient non-affiliated to the social security scheme
• Pregnant or breastfeeding women

Trial design

123 participants in 2 patient groups

group 1

Description:

culprit lesion is infra popliteal

group 2

Description:

culprit lesion is supra or popliteal